November 1, 2016
Multiple label expansions of premium-priced agents and the launch of seven novel therapies will fuel the significant growth of the NHL market over the ten-year forecast period. The biosimilar…
August 31, 2016
Non-Hodgkin’s lymphoma represents a segment of heterogeneous disease with multiple indolent and aggressive subtypes. The antineoplastic treatment rate in B-cell NHL patients is typically high…
July 25, 2016
LaunchTrends: Venclexta (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched chronic…